Johnson & Johnson JNJ Q3 2023 Earnings Call Transcript The Motley Fool

negative retained earnings

In the case of STELARA, that represents about 25% of the sales. So with the upcoming readouts, filing and potential approvals of ulcerative colitis and Chron’s disease, we expect to have significant growth in TREMFYA. We talk about TREMFYA as a $5 billion product earlier in our Analyst Day in 2021. Now you can see clearly that we’re going not only to meet that, but to clearly exceed that benchmark for TREMFYA.

Bloom Energy (BE): A Smart Investment or a Value Trap? An In … –

Bloom Energy (BE): A Smart Investment or a Value Trap? An In ….

Posted: Mon, 16 Oct 2023 15:03:48 GMT [source]

This is Jessica Moore, Vice President of Investor Relations for Johnson & Johnson. Welcome to our company’s review of the 2023 third quarter business results and full-year financial outlook. However, by implementing sound financial strategies, companies can recover from retained losses and rebuild their financial position. To mitigate these risks, companies negative retained earnings must diligently monitor their retained earnings and adopt appropriate measures to avoid negative balances. Various factors such as increased expenses, declining sales, poor management decisions, or economic downturns can contribute to this predicament. Dave, a self-taught investor, empowers investors to start investing by demystifying the stock market.

Negative Retained Earnings: Definition, Impacts, and Effects

This was primarily driven by higher unrealized mark-to-market losses on public securities, partially offset by the lower COVID-19 vaccine-related exit costs and lower litigation expense. Restructuring in the third quarter was $158 million, primarily related to the Innovative Medicine restructuring program announced in the first quarter. Worldwide MedTech sales of $7.5 billion increased to 10% with growth of 11.6% in the U.S. and 8.3% outside of the U.S. Regarding share count given the Kenvue separation, the full benefit of the approximately 191 million net share reduction in Johnson & Johnson shares outstanding from the exchange offer will be reflected in our 2024 financials.

  • By subtracting dividends from net income, you can see how much of the company’s profit gets reinvested into the business.
  • So we’ll have some clearly inventory write-downs as a result of that.
  • The amount of additional paid-in capital is determined solely by the number of shares a company sells.
  • Thus, if the company had a market value of $2 million before the stock dividend declaration, it’s market value still is $2 million after the stock dividend is declared.
  • Its equity value is, therefore, $220 million or $4.40 per share.
  • Both retained earnings and reserves are essential measures of a company’s financial health.

You are also going to see data being presented at ESMO, very important for us. Certainly, we have always been very confident in being able to hit our $57 billion target in 2025 for pharma. As I have explained before, there are a number of factors there are. The first one and most important is the growth that we’re having in our key assets Tremfya, Erleada, Uptravi, our long-acting injectables, and especially Darzalex. But wanted to check on how beneficial is the extra year for the Innovative Medicine businesses defense strategy. I guess, focusing on just the potential for Tremfya to take share from — psoriasis and psoriatic arthritis and inflammatory bowel disease indications.


We are very pleased overall, as I said, with our immunology portfolio. Overall, our immunology portfolio in the quarter grew 12.4%, which is very strong considering that we also have headwinds there of REMICADE biosimilars. And we remain very excited about the immunology portfolio as a key driver for J&J. And first, let me say that China for us is a key market, and a market in which we are delivering growth now, and we are going to continue to deliver a strong growth into 2024.


Your email address will not be published. Required fields are marked *